**Claims**

1. A compound, 3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3,4]octan-1-yl]-3-oxopropanenitrile or a pharmaceutically acceptable salt thereof, for use in the treatment of alopecia areata.

2. The compound for use according to claim 1 wherein the treatment is topical.

3. The compound for use according to claim 1 or 2 wherein the compound is administered in an ointment.

4. The compound for use according to claim 3 wherein the concentration of the compound in the ointment is 0.3% by weight.

5. The compound for use according to claim 3 wherein the concentration of the compound in the ointment is 1% by weight.


6. The compound for use according to claim 3 wherein the concentration of the compound in the ointment is 3% by weight.

7. The compound for use according to any of the one of the preceding claims wherein the compound is administered in an amount of 1.7 mg/cm$^2$.

8. The compound for use according to any of the one of the preceding claims wherein the compound is administered as a twice daily application.

9. The compound for use according to claim 8, wherein the compound is administered as a twice daily application for 12 weeks.

10. A therapeutic or preventive agent for use in the treatment of alopecia areata, comprising a compound represented by the following chemical structural formula:




or a pharmaceutically acceptable salt thereof, as an active ingredient.

11. The therapeutic or preventive agent for use in the treatment of alopecia areata according to claim 10, wherein the pharmaceutical composition is a topical agent.

12. The therapeutic or preventive agent for use in the treatment of alopecia areata according to claim 11,wherein the topical agent is an ointment.

13. The therapeutic or preventive agent for use in the treatment of alopecia areata according to claim 12, wherein the concentration of 3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile is 0.3% by weight.

14. The therapeutic or preventive agent for use in the treatment of alopecia areata according to claim 12, wherein the concentration of 3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile is 1% by weight.

**15.** The therapeutic or preventive agent for use in the treatment of alopecia areata according to claim 12, wherein the concentration of 3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile is 3% by weight.

**16.** A pharmaceutical composition for use in the treatment of alopecia areata, comprising 3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro-[3,4]octan-1-yl]-3-oxopropanenitrile, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier(s).